ArriVent Biopharma, Inc. (AVBP) is a publicly traded company in the Unknown sector. Across all available filings, 9 corporate insiders have executed 30 transactions totaling $34.0M, demonstrating a bullish sentiment with $34.0M in net insider flow. The most recent transaction on Feb 2, 2026 involved a transaction of 130,000 shares valued at $0.
No significant insider buying has been recorded for AVBP in the recent period.
No significant insider selling has been recorded for AVBP in the recent period.
Based on recent SEC filings, insider sentiment for AVBP is bullish with an Insider Alignment Score of 100/100 and a net flow of $34.0M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at ArriVent Biopharma, Inc. (AVBP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 9 insiders are actively trading AVBP stock, having executed 30 transactions in the past 90 days. The most active insider is Advisors, Ltd. Hhlr (Executive), who has made 3 transactions totaling $10.0M.
Get notified when executives and directors at AVBP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Paul Kastenmayer James | General Counsel | Award | 130,000 | $N/A | $0 | |
| Feb 2, 2026 | Yao Zhengbin | Executive | Award | 550,000 | $N/A | $0 | |
| Feb 2, 2026 | Kung Winston | Chief Financial Officer | Award | 140,000 | $N/A | $0 | C-Suite |
| Feb 2, 2026 | Lutzker Stuart | Executive | Award | 150,000 | $N/A | $0 | |
| Feb 2, 2026 | Lachapelle Robin | Chief Operating Officer | Award | 130,000 | $N/A | $0 | C-Suite |
| Jul 11, 2025 | Lachapelle Robin | Executive | Option Exercise | 2,600 | $2.28 | $5.9K | |
| Jul 11, 2025 | Lachapelle Robin | Executive | Option Exercise | 6,503 | $2.28 | $14.8K | |
| Jul 11, 2025 | Lachapelle Robin | Executive | Option Exercise | 2,050 | $2.28 | $4.7K | |
| Sep 19, 2024 | Lachapelle Robin | Executive | Option Exercise | 2,867 | $2.28 | $6.5K | |
| Sep 19, 2024 | Lachapelle Robin | Executive | Option Exercise | 2,700 | $6.24 | $16.8K | |
| Sep 19, 2024 | Lachapelle Robin | Executive | Option Exercise | 7,164 | $2.28 | $16.3K | |
| Sep 19, 2024 | Lachapelle Robin | Executive | Option Exercise | 12,364 | $3.65 | $45.1K | |
| Sep 19, 2024 | Lachapelle Robin | Executive | Option Exercise | 2,471 | $2.28 | $5.6K | |
| Jan 30, 2024 | Healy James | Executive | Purchase | 444,444 | $18.00 | $8.0M | Large |
| Jan 30, 2024 | Healy James | Executive | Conversion | 1,252,308 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 6 | $34.0M | 99.7% |
Exercise(M) | 8 | $115.9K | 0.3% |
Award(A) | 5 | $0 | 0.0% |
Conversion(C) | 11 | $0 | 0.0% |
Insiders at ArriVent Biopharma, Inc. are accumulating shares at an accelerated pace. With 9 insiders making 30 transactions totaling $34.0M in purchases versus $0 in sales, the net buying activity of $34.0M signals strong executive confidence. Advisors, Ltd. Hhlr (Executive) leads the buying activity with $10.0M in transactions across all time.